<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199198</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0862</org_study_id>
    <nct_id>NCT01199198</nct_id>
  </id_info>
  <brief_title>Tolvaptan in Hyponatremic Cancer Patients</brief_title>
  <official_title>Randomized Placebo-Controlled Trial of Tolvaptan in Hyponatremic Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if tolvaptan can help raise salt&#xD;
      (sodium) levels in the cancer patients' blood by removing extra body water as urine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drug:&#xD;
&#xD;
      Tolvaptan is designed to help raise salt levels in your blood by removing extra body water as&#xD;
      urine.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be randomly assigned (as&#xD;
      in the flip of a coin) to 1 of 2 groups. You will have an equal chance of being assigned to&#xD;
      either group:&#xD;
&#xD;
        -  If you are in Group 1, you will take tolvaptan and receive standard of care&#xD;
&#xD;
        -  If you are in Group 2, you will take a placebo and receive the standard of care for&#xD;
           patients with hyponatremia. A placebo is a tablet that looks like the study drug but has&#xD;
           no active ingredients.&#xD;
&#xD;
      You will not know which group you are assigned. However, if needed for your safety, you will&#xD;
      be able to find out what you are receiving at any time.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will take tolvaptan or the placebo 1 time every day by mouth for 14 days.&#xD;
&#xD;
      If you are receiving the placebo, you will also receive the standard of care for&#xD;
      hyponatremia. Examples of the standard of care include limiting your water and fluid intake,&#xD;
      or giving you salt tablets and other drugs such as diuretics. Your doctor will describe these&#xD;
      in more detail.&#xD;
&#xD;
      You will be given a drug diary to record when you take the study drug/placebo. You will&#xD;
      return any unused drug/placebo at the end of 14 days.&#xD;
&#xD;
      You should avoid grapefruit and grapefruit juice while you are taking tolvaptan.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      At every visit, you will be asked if you have had any side effects.&#xD;
&#xD;
      On Days 1, 2, and 3:&#xD;
&#xD;
        -  Blood (about 1 teaspoon) will be drawn for routine tests. On Day 1, this sample will be&#xD;
           drawn 2 times.&#xD;
&#xD;
        -  Your weight and vital signs will be measured.&#xD;
&#xD;
        -  The study staff will record how much fluid you are drinking and how much you are&#xD;
           urinating.&#xD;
&#xD;
        -  You will be asked about any drugs that you may be taking.&#xD;
&#xD;
        -  If the doctor thinks it is needed, you will have a physical exam.&#xD;
&#xD;
      On Day 7:&#xD;
&#xD;
        -  Your medical history will be reviewed and updated.&#xD;
&#xD;
        -  You will be asked about any drugs that you may be taking.&#xD;
&#xD;
        -  Blood (about 1 teaspoon) will be drawn for routine tests and tests to measure how&#xD;
           concentrated your blood results are.&#xD;
&#xD;
        -  Your weight and vital signs will be measured.&#xD;
&#xD;
      On Day 14:&#xD;
&#xD;
        -  Your medical history will be reviewed and updated.&#xD;
&#xD;
        -  Your weight and vital signs will be measured.&#xD;
&#xD;
        -  Blood (about 1 teaspoon) and urine will be collected for routine tests and tests to&#xD;
           measure how concentrated your blood and urine are.&#xD;
&#xD;
        -  The study staff will record how much fluid you are drinking and how much you are&#xD;
           urinating.&#xD;
&#xD;
        -  You will be asked about any drugs that you may be taking.&#xD;
&#xD;
        -  You will complete the MMSE.&#xD;
&#xD;
      If the doctor thinks it is needed, you will have a physical exam.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will take the study drug/placebo for 14 days. You will be taken off study if you have&#xD;
      intolerable side effects, if the disease gets worse, or if the study doctor thinks it is in&#xD;
      your best interest.&#xD;
&#xD;
      Your participation on the study will be over once you have completed the end-of-study visit.&#xD;
&#xD;
      End-of-Study- Day 30 Follow-up Visit:&#xD;
&#xD;
      At 30 days after the last dose of study drug (or placebo), you will have an end-of-study&#xD;
      visit in clinic or by telephone. At this visit, the following tests and procedures will be&#xD;
      performed.&#xD;
&#xD;
        -  Your medical history will be reviewed and updated.&#xD;
&#xD;
        -  Blood (about 1 teaspoon) will be drawn for routine tests and tests to measure how&#xD;
           concentrated your blood results are.&#xD;
&#xD;
        -  You will be asked about any side effects that you may be having and any drugs that you&#xD;
           may be taking.&#xD;
&#xD;
        -  The study staff will record how much fluid you are drinking and how much you are&#xD;
           urinating.&#xD;
&#xD;
        -  If the doctor thinks it is needed, you will have a physical exam.&#xD;
&#xD;
      This is an investigational study. Tolvaptan is FDA approved and commercially available to&#xD;
      treat hyponatremia (low levels of salt [sodium] in the blood due to too much body water). Its&#xD;
      use in patients with cancer who have hyponatremia is investigational.&#xD;
&#xD;
      Up to 170 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Whose Serum Sodium Concentration Corrected to at Least 135 mEq/L on Day 14</measure>
    <time_frame>14 days</time_frame>
    <description>Compare proportion of hyponatremia cancer patients with a normalized serum sodium concentration at day 14 between those treated with Tolvaptan and those treated with a placebo (standard of care). Proportion of participants whose serum sodium concentration is corrected to at least 136 mEq/Lon day14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in Hospital</measure>
    <time_frame>From administration of treatment to time of discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>Tolvaptan Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tolvaptan Group: Starting dose 15 mg by mouth once a day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Group: Placebo by mouth once a day for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>Starting dose 15 mg by mouth once a day for 14 days.</description>
    <arm_group_label>Tolvaptan Group</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth once a day for 14 days.</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Euvolemic or hypervolemic (patients with heart or liver failure) with cancer admitted&#xD;
             to MD Anderson Cancer Center for any reasons with serum sodium between 125 and 130&#xD;
             mEq/L (both inclusive)&#xD;
&#xD;
          2. Patients must be greater than or equal to 18 years of age&#xD;
&#xD;
          3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 at&#xD;
             baseline.&#xD;
&#xD;
          4. Women of childbearing potential must use a medically accepted method of contraception&#xD;
             and to continue use of this method for the duration of the study and for 30 days after&#xD;
             study participation. Acceptable methods of contraception include abstinence, barrier&#xD;
             method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral,&#xD;
             transdermal, implanted, and injected) in conjunction with a barrier method. Men must&#xD;
             practice abstinence or use a barrier method of birth control, and must agree to&#xD;
             continue use for the duration of the study and for 30 days after study participation.&#xD;
&#xD;
          5. Subjects must be able to comply with scheduled visits and follow-ups.&#xD;
&#xD;
          6. Informed consent must be signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to tolvaptan&#xD;
&#xD;
          2. Patients admitted to the critical care unit.&#xD;
&#xD;
          3. Patients with renal failure(creatinine clearance less than 25 ml/min)&#xD;
&#xD;
          4. Patients with a life expectancy less than 3 months&#xD;
&#xD;
          5. Patients with volume depletion, BP &lt; 100/60 or urinary sodium &lt;20 meq/L.&#xD;
&#xD;
          6. Patients who are not able to swallow or cannot take medication through feeding tubes&#xD;
&#xD;
          7. Patients with diuretic-induced hyponatremia.&#xD;
&#xD;
          8. Patients with spurious hyponatremia&#xD;
&#xD;
          9. Patients with hyponatremia related to psychogenic polydypsia, head trauma, post&#xD;
             operative conditions, uncontrolled hypothyroidism or cortisol insufficiency or any&#xD;
             hyponatremia associated with the use of medication that can be safely withdrawn.&#xD;
&#xD;
         10. The use of alcohol while participating in the study&#xD;
&#xD;
         11. Currently taking demeclocycline, lithium, benzazepine derivatives, ketoconazole,&#xD;
             grapefruit, grapefruit juice and receiving strong CYP3A inhibitors such as&#xD;
             clarithromycin, fluconazole, voriconazole, posaconazole, itraconazole, ritonavir,&#xD;
             indinavir, nelfinavir, saquinavir, nefazodone, and telithromycin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdulla K. Salahudeen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <results_first_submitted>September 2, 2020</results_first_submitted>
  <results_first_submitted_qc>September 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2020</results_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyponatremia</keyword>
  <keyword>Serum sodium</keyword>
  <keyword>Tolvaptan</keyword>
  <keyword>Placebo</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: May 5, 2011 to July 13, 2012. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 52 participants enrolled, only 48 patients were randomized to participate in the study. Two participants were not randomized due to contra indicated medication and another two were not randomized due to exclusion criteria. The study was stopped for superiority.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tolvaptan Group</title>
          <description>Starting dose 15 mg orally once a day for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Placebo orally once a day for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ICU Transfer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hospice-care transfer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline demographics and clinical characteristics of patients in the placebo group and the Tolvaptan Group who completed the 14-Day study.</population>
      <group_list>
        <group group_id="B1">
          <title>Tolvaptan Group</title>
          <description>Starting dose 15 mg orally once a day for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Placebo orally once a day for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="36" upper_limit="60"/>
                    <measurement group_id="B2" value="69" lower_limit="52" upper_limit="81"/>
                    <measurement group_id="B3" value="65" lower_limit="36" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Whose Serum Sodium Concentration Corrected to at Least 135 mEq/L on Day 14</title>
        <description>Compare proportion of hyponatremia cancer patients with a normalized serum sodium concentration at day 14 between those treated with Tolvaptan and those treated with a placebo (standard of care). Proportion of participants whose serum sodium concentration is corrected to at least 136 mEq/Lon day14.</description>
        <time_frame>14 days</time_frame>
        <population>&quot;Evaluable participants&quot; are defined as all participants excluding those who drop out of the study due to non-study related reasons. Participants who are lost to follow-up for unknown or study related reasons will be counted as failures based on the intent to treat principal.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan Group</title>
            <description>Starting dose 15 mg orally once a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo orally once a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Whose Serum Sodium Concentration Corrected to at Least 135 mEq/L on Day 14</title>
          <description>Compare proportion of hyponatremia cancer patients with a normalized serum sodium concentration at day 14 between those treated with Tolvaptan and those treated with a placebo (standard of care). Proportion of participants whose serum sodium concentration is corrected to at least 136 mEq/Lon day14.</description>
          <population>&quot;Evaluable participants&quot; are defined as all participants excluding those who drop out of the study due to non-study related reasons. Participants who are lost to follow-up for unknown or study related reasons will be counted as failures based on the intent to treat principal.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay in Hospital</title>
        <time_frame>From administration of treatment to time of discharge</time_frame>
        <population>&quot;Evaluable participants&quot; are defined as all participants excluding those who drop out of the study due to non-study related reasons. Participants who are lost to follow-up for unknown or study related reasons will be counted as failures based on the intent to treat principal.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan Group</title>
            <description>Starting dose 15 mg orally once a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo orally once a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in Hospital</title>
          <population>&quot;Evaluable participants&quot; are defined as all participants excluding those who drop out of the study due to non-study related reasons. Participants who are lost to follow-up for unknown or study related reasons will be counted as failures based on the intent to treat principal.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="15"/>
                    <measurement group_id="O2" value="26" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collection through follow up, anticipated Day 30 +/- 5 days. Overall collection period: May 10, 2011 to August 24, 2012.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tolvaptan Group</title>
          <description>Starting dose 15 mg orally once a day for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Placebo orally once a day for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Worsening of Edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections (any type)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carmen Escalante,MD/Chair, General Internal Med</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>(713) 745-4516</phone>
      <email>cescalan@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

